| name | Diloxanide Furoate |
| Classification | Antiprotozoal (amoebicide) |
| Pharmacokinetics | Diloxanide furoate is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations are reached within 1-2 hours. It is distributed throughout the body, including the liver and intestinal tract. The drug is primarily excreted in the urine. The drug's half-life varies, typically between 2-3 hours. However, significant variability in absorption and metabolism can occur in individuals. |
| suggested dosage | | adult | | amoebiasis | 500 mg three times daily for 10 days. Some sources suggest 2-3 g total per day in divided doses for a week, or for a shorter course, 1-2 g/day (3-6 tablets/day) given in divided doses as well. Consult a physician for specific dosage recommendations. The recommended dosage is heavily influenced by the severity and type of the infection. | | other indications | Dosage varies considerably depending on the specific indication and patient factors. Always consult a healthcare professional for appropriate dosage. |
| | notes | Dosage must be individualized based on the specific patient's condition and other medications the patient is taking. The dosage should not be exceeded without consulting a doctor. Children's dosage differs and is not included here. |
|
| indications | Diloxanide furoate is primarily used for the treatment of amebiasis, an infection caused by the parasite Entamoeba histolytica. The medicine works by interfering with the parasite's metabolic processes. Diloxanide furoate is often used in combination with other medications or as a follow-up treatment for severe infection. |
| safety in pregnancy | Limited data is available on the use of diloxanide furoate during pregnancy. Consult a physician. Potential risks and benefits should be carefully evaluated. It's important to weigh risks and benefits and ideally avoid the drug during pregnancy, unless absolutely necessary, as safety is not fully established. |
| safety in breastfeeding | Limited information exists regarding the use of diloxanide furoate during breastfeeding. Potential risks and benefits should be evaluated, preferably in consultation with a doctor. The use of this medicine in breastfeeding mothers needs careful consideration. It's best to avoid using diloxanide furoate while breastfeeding if possible and use alternative treatments where suitable. |
| side effects | | 1 | Nausea | | 2 | Vomiting | | 3 | Diarrhea | | 4 | Abdominal cramps | | 5 | Headache | | 6 | Metallic taste | | 7 | Skin rash | | 8 | Gastrointestinal upset | | 9 | Stomach pain | | 10 | Loss of appetite | | 11 | Dizziness |
|
| alternatives | |
| contraindications | Known hypersensitivity to diloxanide furoate or any of its components. Severe liver disease. Children and adolescents should not be given this drug without consulting a healthcare provider. |
| interactions | Information on drug interactions is limited but there may be interactions with other medications. Consult with your physician before using other medications, including over-the-counter medications. The effect on other medications is unpredictable. |
| warnings and precautions | Diloxanide furoate can cause severe side effects in some people. Symptoms of severe side effects should be reported to a medical professional immediately. Avoid alcohol consumption during treatment. Important to follow the prescribed course of treatment completely to ensure effectiveness and minimize potential complications. Monitor symptoms. |
| additional information | Diloxanide furoate is not a first-line treatment for amebiasis in many cases. More effective and better-tolerated options may be available. Always seek guidance from a qualified healthcare professional. Consult with a physician about the need for this medication and for appropriate diagnosis and treatment. |
| patient details | |
